HRTX - Heron Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
26.71
-1.14 (-4.09%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close27.85
Open27.66
Bid25.25 x 900
Ask27.10 x 800
Day's Range26.29 - 28.14
52 Week Range15.00 - 42.90
Volume1,029,127
Avg. Volume1,022,257
Market Cap2.084B
Beta (3Y Monthly)1.76
PE Ratio (TTM)N/A
EPS (TTM)-3.14
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.00
Trade prices are not sourced from all markets
  • U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics
    PR Newswire6 days ago

    U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics

    SAN DIEGO, Nov. 12, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today hosted a fireside chat with the U.S. Surgeon General, Vice Admiral Jerome M. Adams, M.D., M.P.H. It was a familiar venue for Dr. Adams, as he continues to visit communities across the country and advocate for forming non-traditional partnerships with businesses, faith-based communities and law enforcement agencies to tackle the opioid crisis. During their meeting with the Surgeon General, Heron leaders and staff discussed the need for new and innovative opioid-free postoperative pain control, as well as the ways that science can help the nation find newer and smarter ways out of an epidemic that resulted in more than 42,000 opioid overdose deaths in 2016 according to data from the Centers for Disease Control and Prevention.

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: Heron Therapeutics and Bristol-Myers Squibb

    According to Willie Delwiche, investment strategist at R.W. Baird, “Oil being down could be a sign that the global economy is in a tough spot.” “The initial reaction to lower oil prices has been that they’ll be a boon for the middle class,” Delwiche said that the view could be inaccurate considering that consumer confidence doesn’t have more chances to grow, and because a smaller part of the American consumer’s budget goes to gasoline than it has in the previous years. The stock recorded a trading volume of 1,456,948 shares, which was above its three months average volume of 998,535 shares. On Friday, shares of Bristol-Myers Squibb recorded a trading volume of 8,107,392 shares, which was above the three months average volume of 7,213,656 shares.

  • Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
    Zacks11 days ago

    Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates

    Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -4.26% and 6.31%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press11 days ago

    Heron Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 49 cents. The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...

  • PR Newswire11 days ago

    Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress

    - Heron Raises Full-Year 2018 CINV Franchise Net Product Sales Guidance to $70 Million to $72 Million - SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage ...

  • PR Newswire18 days ago

    Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management

    SAN DIEGO, Oct. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-011. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain. HTX-011 was granted both Breakthrough Therapy and Fast Track designations from the FDA.

  • GlobeNewswirelast month

    Factors of Influence in 2018, Key Indicators and Opportunity within Cloud Peak Energy, Ralph Lauren, CytomX Therapeutics, Extreme Networks, Heron Therapeutics, and Alteryx — New Research Emphasizes Economic Growth

    NEW YORK, Oct. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Simply Wall St.last month

    Why Heron Therapeutics Inc (NASDAQ:HRTX) Is A Financially Healthy Company

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Heron Therapeutics Inc (NASDAQ:HRTX) with a market-capitalization of US$2.4b, rarely draw their attention. However, history shows that Read More...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Heron Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...

  • PR Newswire2 months ago

    Heron Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018, at 2:20 p.m. EDT at the Intercontinental New York Barclay Hotel. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs.

  • Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options

    Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

  • Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
    Market Realist2 months ago

    Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

    On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.

  • 2 Growth Stocks That Could Make You Rich
    Motley Fool3 months ago

    2 Growth Stocks That Could Make You Rich

    Heron Therapeutics and Intercept Pharmaceuticals could both produce market-crushing returns for investors over the next decade. Here's why.

  • Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

    Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 21.74% and 23.30%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Heron Therapeutics: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 54 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss ...

  • PR Newswire3 months ago

    Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress

    SAN DIEGO , Aug. 8, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Heron Therapeutics and Pfizer

    NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Wall Street snapped its losing streak on Tuesday as investors digested better-than-expected quarterly earnings and after the Trump administration appeared to ...

  • Why Pacira Pharmaceuticals Stock Is on the Rise Today
    Motley Fool4 months ago

    Why Pacira Pharmaceuticals Stock Is on the Rise Today

    The company's shares are rallying today on an analyst upgrade.

  • ACCESSWIRE4 months ago

    Free Pre-Market Technical Recap on Sanofi and Three Additional Drug Makers Stocks

    On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drug Manufacturers - Major equities this morning: Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Sanofi (NYSE: SNY).

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Heron Therapeutics and Array BioPharma

    NEW YORK, NY / ACCESSWIRE / June 28, 2018 / U.S. equities fell sharply on Wednesday, weighed by losses from the consumer staples and technology sectors. The Dow Jones Industrial Average decreased 0.68 ...

  • Is There An Opportunity With Heron Therapeutics Inc’s (NASDAQ:HRTX) 33.58% Undervaluation?
    Simply Wall St.5 months ago

    Is There An Opportunity With Heron Therapeutics Inc’s (NASDAQ:HRTX) 33.58% Undervaluation?

    I am going to run you through how I calculated the intrinsic value of Heron Therapeutics Inc (NASDAQ:HRTX) by projecting its future cash flows and then discounting them to today’sRead More...

  • Business Wire5 months ago

    Heron Therapeutics Announces Pricing of Public Offering of Common Stock

    Heron Therapeutics, Inc. (“Heron”) (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of shares of its common stock. The offering is expected to close on or about June 28, 2018, subject to customary closing conditions.

  • Business Wire5 months ago

    Heron Therapeutics Announces Public Offering of Common Stock

    Heron Therapeutics, Inc. (“Heron”) (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of shares of its common stock. All of the shares of common stock in the offering are to be sold by Heron.

  • Cramer's lightning round: If you want to invest in non-op...
    CNBC Videos26 days ago

    Cramer's lightning round: If you want to invest in non-op...

    Jim Cramer flies through his take on callers' favorite stocks, including that of a biotechnology company developing non-opioid pain medication.